Von Willebrand disease in children in Assiut
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Women’s health & pregnancy clinical trials.
This study looks at children with suspected or confirmed von Willebrand disease (a bleeding disorder) in the Assiut region. It aims to describe their symptoms and how they are managed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 0 and 18 years old
- You live in the Assiut Governorate or receive care at Assiut University Children's Hospital
- You have bleeding symptoms or have been referred for evaluation of von Willebrand disease
- You have been diagnosed with von Willebrand disease through standard lab tests
- You do not have other inherited bleeding disorders like hemophilia or platelet problems
- You do not have an acquired bleeding disorder or take blood-thinning medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests vonicog alfa (an rVWF treatment) to prevent and control bleeding in children with severe von Willebrand disease (vWD). You may be able to join if your child has severe vWD and has been on prior clotting factor treatment with ongoing bleeding despite that care.
This study looks at special cells from blood vessels (endothelial colony-forming cells) in people with von Willebrand disease (a bleeding disorder) or a related acquired condition. The goal is to better understand these conditions using blood donations.
This trial tests whether a special algorithm can reduce repeat bleeding from the gut or nose in people with inherited Von Willebrand disease. If you have had serious nosebleeds or digestive bleeding, this study may help find a better way to manage your condition.
This study is testing a new treatment for people with certain types of Von Willebrand disease (Type 1 or 2A) who have frequent bleeding problems. It aims to see if the treatment can help reduce these bleeding episodes.
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
This study looks at how well vonicog alfa (a lab-made version of a missing blood protein) works to control bleeding in children under 18 with von Willebrand disease. It follows children who are already prescribed this treatment in Japan to see how safe and effective it is in real life.
Hear when a new Von Willebrand Disease (VWD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.